Lifevantage's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Lifevantage's ROA in the fourth quarter of 2026?
Lifevantage Corp achieved a return on average assets (ROA) of 7.82 % in its fourth quarter of 2026, which is below Lifevantage's average return on assets, which stands at 12.72%.

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 119 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2026 from 619 to 721.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Total Assets Change	-11.34 %	-19.56 %	47.51 %	24.2 %	47.51 %
Y / Y Net Income Change	-34.71 %	-60.75 %	-89.18 %	18.02 %	50.11 %
Net Income (TTM) in million	5	6	8	10	10
Return On Assets (TTM)	7.82 %	8.6 %	11.12 %	15.62 %	15.84 %
LFVN's Total Ranking	# 721	# 619	# 352	# 364	# 381
Total Assets (TTM) in million	64	62	72	62	72
Seq. Total Assets Change	2.68 %	-13.66 %	16.85 %	-14.42 %	-6.83 %
Seq. Net Income Change	-6.09 %	393.48 %	-87.19 %	10.01 %	-43.54 %

LFVN's 5 Years Annual ROA >> Back to LFVN Management Effectiveness >> Compare LFVN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 46
Sector	# 120
Overall	# 778

Return On Assets Statistics
High	Average	Low
41.68 %	12.72 %	-1.22 %
(Jun 30 2012)		(Mar 31 2023)

Financial Statements
Lifevantage's Assets	$ 64 million	LFVN's Balance sheet
Lifevantage's Income	$ 1 million	Quarterly LFVN's Income Statement
LFVN's Income by Division		See LFVN's Income by Division

Annual Return On Assets	(Jun 30 2026) FY 2026	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022
Y / Y Total Assets Change	7.5 %	21.66 %	-14.15 %	-5.36 %	-7.48 %
Total Assets in million	64	59	49	57	60
Y / Y Net Income Change	-48.27 %	233.84 %	15.63 %	-18.59 %	-75.8 %
Net Income in million	5	10	3	3	3
Annual Return On Assets	7.95 %	16.52 %	6.02 %	4.47 %	5.2 %

LFVN's 5 Years Annual ROA >> Back to LFVN Management Effectiveness >> Compare LFVN ROA to its Competitors

Comment on LFVN's ROA in the fiscal year ending 2026

In the fiscal year 2026 Lifevantage's ROA decreased compared to previous year to 7.95 %, due to deterioration of net income -48.27 % to $5.07 million, from $9.81 million a year ago, as LFVN's assets were $63.80 million.

More Return On Assets Ratios
LFVN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LFVN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LFVN's Competitors
Subscribers only: Roa for Lifevantage's Suppliers
Subscribers only: Return On Assets for LFVN's Customers

You may also want to know
LFVN's Roi	LFVN's Inventory Turnover Ratio	LFVN's Growth Rates	LFVN's Dividend Comparisons
	LFVN's Profitability Ratios	LFVN's Asset Turnover Ratio	LFVN's Dividend Growth
LFVN's Roe	LFVN's Valuation Ratios	LFVN's Financial Strength Ratios	LFVN's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Vaxart Inc	20.85 %
Zevra Therapeutics Inc	20.39 %
Iradimed Corporation	20.36 %
Protalix Biotherapeutics inc	20.09 %
Pro dex Inc	19.87 %
Electromed Inc	19.39 %
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %
Standard Biotools Inc	14.31 %
Arcutis Biotherapeutics Inc	14.23 %
Harmony Biosciences Holdings inc	14.15 %
Biolife Solutions Inc	14.09 %
Aveanna Healthcare Holdings Inc	13.82 %
West Pharmaceutical Services Inc	13.64 %
Medinotec Inc	13.38 %
Puma Biotechnology Inc	13.28 %
Sbc Medical Group Holdings Incorporated	13.26 %
Alpha Pro Tech Ltd	13.17 %

Date modified: 2026-09-12T06:11:30+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.